Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma
Pancreatology · 2024
DOI: 10.1016/j.pan.2024.02.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pancreatology, 2024. Verfasst von Hyunseok Yoon und 19 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Asan Institute for Life Sciences, Asan Medical Center.
Abstract (Originalsprache)
BACKGROUND: Modified FOLFIRINOX (mFOLFIRINOX) is one of the standard first-line therapies in borderline resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAPC). However, there is no globally accepted second-line therapy following progression on mFOLFIRINOX. METHODS: Patients with BRPC and LAPC (n = 647) treated with first-line mFOLFIRINOX between January 2017 and December 2020 were included in this retrospective analysis. The details of the treatment outcomes and patterns of subsequent therapy after mFOLFIRINOX were reviewed. RESULTS: With a median follow-up duration of 44.2 months (95% confidence interval [CI], 42.3-47.6), 322 patients exhibited disease progression on mFOLFIRINOX-locoregional progression only in 177 patients (55.0%) and distant metastasis in 145 patients (45.0%). The locoregional progression group demonstrated significantly longer post-progression survival (PPS) than that of the distant metastasis group (10.1 vs. 7.3 months, p = 0.002). In the locoregional progression group, survival outcomes did not differ between second-line chemoradiation/radiotherapy and systemic chemotherapy (progression-free survival with second-line therapy [PFS-2], 3.2 vs. 4.3 months; p = 0.649; PPS, 10.7 vs. 10.2 months; p = 0.791). In patients who received second-line systemic chemotherapy following progression on mFOLFIRINOX (n = 211), gemcitabine plus nab-paclitaxel was associated with better disease control rates (69.2% vs. 42.3%, p = 0.005) and PFS-2 (3.8 vs. 1.7 months, p = 0.035) than gemcitabine monotherapy. CONCLUSIONS: The current study showed the real-world practice pattern of subsequent therapy and clinical outcomes following progression on first-line mFOLFIRINOX in BRPC and LAPC. Further investigation is necessary to establish the optimal therapy after failure of mFOLFIRINOX.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Departments of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Departments of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Departments of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Departments of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Departments of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address: yooc@amc.seoul.kr.
Förderung
- Asan Institute for Life Sciences, Asan Medical Center
Zitieren
APA
Yoon, H., Shin, Y., Ryoo, B. Y., Jeong, H., Park, I., Seo, D. W., Lee, S. S., Park, D. H., Song, T. J., Oh, D., Hwang, D. W., Lee, J. H., Song, K. B., Park, Y., Kwak, B. J., Hong, S. M., Park, J. H., Kim, S. C., Kim, K. P., & Yoo, C. (2024). Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma. Pancreatology. https://doi.org/10.1016/j.pan.2024.02.004
Vancouver
Yoon H, Shin Y, Ryoo BY, Jeong H, Park I, Seo DW, et al. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma. Pancreatology. 2024. doi:10.1016/j.pan.2024.02.004
BibTeX
@article{Yoon2024,
author = {Yoon, Hyunseok and Shin, Yeokyeong and Ryoo, Baek-Yeol and Jeong, Hyehyun and Park, Inkeun and Seo, Dong-Wan and Lee, Sang Soo and Park, Do Hyun and Song, Tae Jun and Oh, Dongwook and Hwang, Dae Wook and Lee, Jae Hoon and Song, Ki Byung and Park, Yejong and Kwak, Bong Jun and Hong, Seung-Mo and Park, Jin-Hong and Kim, Song Cheol and Kim, Kyu-Pyo and Yoo, Changhoon},
title = {Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma},
journal = {Pancreatology},
year = {2024},
doi = {10.1016/j.pan.2024.02.004}
}
EUVIMED